title: Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).
abstract: Upon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.
authors.affiliation: New York University School of Medicine ; New York, NY, USA.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Adams
authors.affiliation: Fox Chase Cancer Center ; Philadelphia, PA, USA.
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Goldstein
authors.affiliation: Albert Einstein Medical Center ; Bronx, NY, USA.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.affiliation: New York University School of Medicine ; New York, NY, USA.
authors.forename: Sandra
authors.initials: S
authors.lastname: Demaria
authors.affiliation: Indiana University ; Indianapolis, IN, USA.
authors.forename: Sunil S
authors.initials: SS
authors.lastname: Badve
keywords: TNBC; biomarker; breast cancer; tumor infiltrating lymphocytes